Analysis of a microarray database of human conjunctival epithelium allowed us to propose potential pathways for mucin-type O-glycosylation at the ocular surface. Enzymes involved in the initiation of mucin-type O-glycosylation in human conjunctiva included 13 GALNT isoforms (GALNT1 to 8, -10 to -12, -14, and -20). A previous study using real-time RT-PCR (
Taqman; Invitrogen) revealed 15 isoforms in human conjunctiva.
37 These included, in addition to those reported in this study (with the exception of GALNT20, which was not evaluated previously), GALNT15, and low levels of GALNT9 and -13. Data quality parameters, such as background-to-noise ratios, could be responsible for the lack of correlation in the expression of GALNT9, -13, and -15 between the two methods.
38 In addition to GALNT, six α2-6 sialyltransferases (ST6GalNAc-I, -II, -III, -IV, -V, and -VI) and five α2-3 sialyltransferases (ST3Gal-I, -III, -IV, -V, and -VI) were identified by microarray. In vitro analysis of substrate specificity has revealed, however, that not all sialyltransferases act on mucin-type substrates. ST6GalNAc-I, -II, and -IV mediate the transfer of sialic acid with an α2-6-linkage to GalNAc residues O-glycosidically attached to Ser/Thr, whereas ST6GalNAc-III, -V, and -VI catalyze the addition of sialic acid residues onto gangliosides.
26 As for the α2-3 sialyltransferases, ST3Gal-I and -IV have been shown to act on Galβ1-3GalNAc present on glycoproteins and glycolipids,
39 40 therefore, constituting potential candidates to synthesize α2-3 sialyl core 1 in conjunctival mucin. By contrast, ST3Gal-III exhibits preference for Galβ1-3GlcNAc structures
41 ; the ST3Gal-VI mainly uses Galβ1-4GlcNAc as an acceptor substrate
42 ; and the ST3Gal-V only acts on glycolipids.
27 Enzymatic assays using suitable substrates for the glycosyltransferases identified in this study would provide valuable information toward further characterization of the acceptor specificity and kinetic mechanisms of these enzymes.